321 related articles for article (PubMed ID: 34737044)
1. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
[TBL] [Abstract][Full Text] [Related]
2. Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors.
Gustafsson G; Eriksson F; Möller C; da Fonseca TL; Outeiro TF; Lannfelt L; Bergström J; Ingelsson M
Cell Mol Neurobiol; 2017 Jan; 37(1):121-131. PubMed ID: 26961542
[TBL] [Abstract][Full Text] [Related]
3. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
6. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
8. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
9. Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease.
Espay AJ; Lees AJ
Parkinsonism Relat Disord; 2024 May; 122():106077. PubMed ID: 38461037
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
Alzghool OM; van Dongen G; van de Giessen E; Schoonmade L; Beaino W
Mov Disord; 2022 May; 37(5):936-948. PubMed ID: 35289424
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.
Lindström V; Fagerqvist T; Nordström E; Eriksson F; Lord A; Tucker S; Andersson J; Johannesson M; Schell H; Kahle PJ; Möller C; Gellerfors P; Bergström J; Lannfelt L; Ingelsson M
Neurobiol Dis; 2014 Sep; 69():134-43. PubMed ID: 24851801
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy.
Chu WT; Hall J; Gurrala A; Becsey A; Raman S; Okun MS; Flores CT; Giasson BI; Vaillancourt DE; Vedam-Mai V
ACS Chem Neurosci; 2023 Jan; 14(2):235-245. PubMed ID: 36571847
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson's disease.
Gou DH; Huang TT; Li W; Gao XD; Haikal C; Wang XH; Song DY; Liang X; Zhu L; Tang Y; Ding C; Li JY
Redox Biol; 2021 Jan; 38():101795. PubMed ID: 33232911
[TBL] [Abstract][Full Text] [Related]
16. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
17. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
19. Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.
Upcott M; Chaprov KD; Buchman VL
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885933
[TBL] [Abstract][Full Text] [Related]
20. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
